Mark D. Rahn

MTI Partners Ltd (MTI Partners) is an independent venture capital firm founded in 1983. The firm is headquartered in UK.

APIS Assay Technologies Ltd. engages in clinical potential of systems biology in the diagnosis of treatment. The company is headquartered in Manchester, the United Kingdom.

MTI Partners Ltd (MTI Partners) is an independent venture capital firm founded in 1983. The firm is headquartered in UK.

Bioxydyn Ltd. provides magnetic resonance imaging applications and services. Its services include imaging protocol and charter, on-site and remote training, quality management, and quantitative imaging biomarkers. The company was founded by Geoffrey James Martin Parker in 2009 and is headquartered in Manchester, the United Kingdom.

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.

MTI Partners Ltd (MTI Partners) is an independent venture capital firm founded in 1983. The firm is headquartered in UK.

MTI Partners Ltd (MTI Partners) is an independent venture capital firm founded in 1983. The firm is headquartered in UK.

APIS Assay Technologies Ltd. engages in clinical potential of systems biology in the diagnosis of treatment. The company is headquartered in Manchester, the United Kingdom.

Bioxydyn Ltd. provides magnetic resonance imaging applications and services. Its services include imaging protocol and charter, on-site and remote training, quality management, and quantitative imaging biomarkers. The company was founded by Geoffrey James Martin Parker in 2009 and is headquartered in Manchester, the United Kingdom.

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.

Renephra Ltd. develops medical devices. Its is developing ground-breaking new approaches to dialysis treatment in end-stage renal disease by accessing the interstitial fluid in the skin. This new approach enables water and toxin removal in a non-invasive manner. The company was founded by Paul Brenchley and Sandip Mitra in 2009 and is headquartered in Manchester, the United Kingdom.

APIS Assay Technologies Ltd. engages in clinical potential of systems biology in the diagnosis of treatment. The company is headquartered in Manchester, the United Kingdom.